Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Mirum Pharmaceuticals, Inc. MIRM

Healthcare  —  Biotechnology
89.70 0.34 0.38% as of 25 Sep
Market cap
$5.8B
P/E
0.0×
Cash Flow Champion (3y) Revenue Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Mirum Pharmaceuticals, Inc. (MIRM) Business Profile

Updated before January 2025

Company Overview

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a biopharmaceutical company dedicated to transforming the treatment landscape for rare liver diseases. Founded in 2018 and headquartered in Foster City, California, Mirum focuses on developing and commercializing innovative therapies for debilitating liver conditions, particularly those affecting children and adults. The company was co-founded by Michael Grey, a seasoned executive in the biotech industry, and is currently led by Chris Peetz, who serves as the President and Chief Executive Officer. Under Peetz’s leadership, Mirum has rapidly advanced its pipeline and achieved significant milestones in the development and commercialization of its products.

Mirum’s mission is to address unmet medical needs in hepatology by delivering life-changing therapies. The company has built a robust portfolio of products and a strong pipeline of investigational drugs, positioning itself as a leader in the rare liver disease space. With a focus on patient-centric innovation, Mirum collaborates with healthcare providers, researchers, and patient advocacy groups to ensure its therapies make a meaningful impact on patients’ lives.

Core Business Segments

Mirum Pharmaceuticals operates primarily in the biopharmaceutical sector, with a focus on rare liver diseases. The company’s core business segments include:

1. Approved Therapies

Mirum has successfully developed and commercialized therapies for rare liver diseases. Its flagship product, Livmarli® (maralixibat), is an oral solution approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS), a rare genetic disorder that affects the liver, heart, and other parts of the body. Livmarli has been a game-changer for patients suffering from the debilitating symptoms of ALGS, offering a non-invasive treatment option.

2. Pipeline Products

Mirum is actively advancing a pipeline of investigational therapies targeting other rare liver diseases. Key pipeline candidates include:

  • Volixibat: A novel therapy under investigation for the treatment of primary sclerosing cholangitis (PSC) and intrahepatic cholestasis of pregnancy (ICP).
  • Expanded Indications for Livmarli: Mirum is exploring the potential of Livmarli to treat other cholestatic liver diseases, such as progressive familial intrahepatic cholestasis (PFIC).

3. Patient Support Services

Mirum is committed to supporting patients and their families through its comprehensive patient assistance programs. These services include financial assistance, educational resources, and personalized support to ensure patients have access to the therapies they need.

Business Model

Mirum Pharmaceuticals operates on a business model centered around innovation, patient-centricity, and strategic partnerships. The company generates revenue primarily through the sale of its approved therapies, such as Livmarli, and aims to expand its revenue streams by obtaining regulatory approvals for additional indications and pipeline products. Mirum also collaborates with academic institutions, research organizations, and pharmaceutical companies to accelerate drug development and expand its market reach.

The company invests heavily in research and development (R&D) to maintain a competitive edge and address unmet medical needs. By focusing on rare liver diseases, Mirum has carved out a niche in the biopharmaceutical industry, allowing it to command premium pricing for its therapies. Additionally, Mirum’s patient support programs enhance patient adherence and satisfaction, further driving revenue growth.

Strategic Direction

Mirum Pharmaceuticals has a clear strategic vision aimed at long-term growth and sustainability. Key elements of its strategic direction include:

  • Pipeline Expansion: Mirum is committed to advancing its pipeline of investigational therapies, with a focus on addressing additional rare liver diseases. The company is conducting clinical trials to evaluate the safety and efficacy of its pipeline candidates, including volixibat and expanded indications for Livmarli.
  • Global Market Expansion: Mirum is actively pursuing regulatory approvals in international markets to expand the availability of its therapies. The company has already achieved approvals in several countries and is working to secure additional approvals in Europe, Asia, and Latin America.
  • Sustainability Goals: Mirum is dedicated to minimizing its environmental footprint and promoting sustainability across its operations. The company is implementing eco-friendly practices in its manufacturing processes and supply chain management.
  • Patient Advocacy and Education: Mirum collaborates with patient advocacy groups and healthcare providers to raise awareness about rare liver diseases and improve patient outcomes. The company also invests in educational initiatives to empower patients and their families.

Competitive Landscape

Mirum Pharmaceuticals operates in a competitive biopharmaceutical market, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Albireo Pharma, Inc.: A biopharmaceutical company focused on developing therapies for rare pediatric liver diseases. Albireo’s product, Bylvay, is a direct competitor to Livmarli.
  • Intercept Pharmaceuticals, Inc.: Known for its work in liver diseases, including nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC).
  • Retrophin, Inc.: A company specializing in rare diseases, including those affecting the liver.

Despite the competition, Mirum differentiates itself through its focus on patient-centric innovation, robust pipeline, and comprehensive patient support programs.

Risk Factors

Like any biopharmaceutical company, Mirum Pharmaceuticals faces several risks, including:

  • Regulatory Risks: The approval process for new drugs is lengthy and uncertain. Delays or rejections by regulatory agencies could impact Mirum’s growth.
  • Market Dependence: Mirum relies heavily on the success of Livmarli for revenue generation. Any issues with the product, such as safety concerns or competition, could adversely affect the company.
  • Supply Chain Disruptions: The company’s operations depend on a reliable supply chain for raw materials and manufacturing. Disruptions could delay product availability.
  • Financial Risks: As a relatively young company, Mirum may face challenges in securing funding for R&D and commercialization efforts.

Recent Developments

Mirum Pharmaceuticals has achieved several milestones in recent years, including:

  • Regulatory Approvals: Livmarli received FDA approval for the treatment of cholestatic pruritus in ALGS and has been approved in multiple international markets.
  • Clinical Trial Progress: The company has made significant progress in clinical trials for volixibat and expanded indications for Livmarli.
  • Partnerships and Collaborations: Mirum has entered into strategic partnerships to enhance its R&D capabilities and expand its market reach.
  • Corporate Initiatives: The company has implemented initiatives to improve operational efficiency and sustainability.

Investment Considerations

Investors considering Mirum Pharmaceuticals should weigh the following factors:

Strengths

  • Strong Market Position: Mirum is a leader in the rare liver disease space, with a proven track record of innovation.
  • Robust Pipeline: The company’s pipeline of investigational therapies offers significant growth potential.
  • Patient-Centric Approach: Mirum’s commitment to patient support enhances its reputation and marketability.

Risks

  • Regulatory and Market Risks: Dependence on regulatory approvals and market acceptance poses challenges.
  • Financial Uncertainty: As a growing company, Mirum may face funding challenges.
  • Competitive Pressure: The biopharmaceutical market is highly competitive, with several players targeting similar indications.

Conclusion

Mirum Pharmaceuticals, Inc. is a dynamic biopharmaceutical company with a strong focus on rare liver diseases. Through its innovative therapies, robust pipeline, and patient-centric approach, Mirum has established itself as a leader in the field. While the company faces challenges such as regulatory risks and market competition, its strategic vision and commitment to addressing unmet medical needs position it for long-term growth. Investors seeking exposure to the biopharmaceutical sector may find Mirum an attractive opportunity, given its strong market position and growth potential.